Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Fight against cancer: EU research develops cancer-killing isotopes

26.06.2002


Highly promising results from clinical trials indicate that alpha-emitting radioisotopes can kill cancer cells. The Commission’s Joint Research Centre (JRC) and Deutsches Krebsforschungszentrum presented this innovative therapy during a recent workshop in Heidelberg. Alpha-immunotherapy should develop into an effective treatment over the next few years and provide new methods of healing for patients. How does the cancer-killing mechanism work? A cancer-cell selective vehicle, (e.g. a monocolonal antibody or a peptide) is connected to a powerful radioactive isotope. As it radioactively decays, the isotope emits particles that can either directly or indirectly kill any cancer cells it encounters. Said EU Research Commissioner Philippe Busquin: "More research is needed, but experts tell us that the results from pre-clinical and first clinical trials are promising. Search-and-destroy isotopes should be helpful in fighting a great number of cancers such as leukaemia, lymphoma (haematological malignancies), microscopic, intraperitoneally growing cancers (e.g. ovarian, stomach), glioblastoma and post-operative treatment of glioma, melanomas, colon tumours, myeloma and palliative treatment of malignant ascites. Multi-disciplinary co-operations between Europe’s best teams are needed to advance this innovative approach. Cancer is a key priority in the EU’s next research programme, to be launched later this year."



One of the key targets of the European Commission’s Sixth Framework programme for Research and Development (2003-2006) is "Combating cancer". Altogether just over €1 billion is earmarked for combating major diseases, of which at least € 400 million should go to cancer research. The objective is to develop better strategies, from prevention to diagnosis and treatment, for fighting cancer. EU research will concentrate on translating the new knowledge being created by genomics and other fields of basic research into applications that improve clinical practice and public health.

As far as research on cancer-killing isotopes is concerned, currently only two organisations world-wide are able to produce such isotopes: the European Commission’s Institute for Transuranium Elements (a branch of the JRC) and the Oak Ridge National Laboratories in the US.


Both the recent results obtained in clinical studies, using bismuth-213 to combat acute myeloid leukaemia, and the first evaluations of the direct use of actinium-225, point to the right direction. Whereas the first isotope emits only one alpha particle during its decay, the latter has a decay chain with 4 alpha particles and could be much more efficient, at least when its full potential can be exploited. At the highest dosage level used (up to100 mCi bismuth-213), no acute toxicity was observed. This breakthrough opens the way for accepting the analyses of other alpha-emitters in a clinical setting also.

The Commission has supported pioneering work at the Deutsches Krebsforschungszentrum (DKFZ) and the Kantonspital of Basel, where the first patients were treated for Non-Hodgkin’s lymphoma and glioblastoma respectively. To date, 37 patients in the US have been treated with bismuth 213 or astatine 211 and 11 patients in Europe.

Other very promising studies on treating melanoma using local antibody conjugated bismuth-213 injection foster scientific understanding and several hypotheses on the operating mechanisms of alpha-damage can therefore be validated. As the use of highly radiotoxic alpha-emitting isotopes is not currently common practice in hospitals, strict requirements need to be respected to allow the large-scale application of this technology.

State-of-the art genomics and proteomics are expected to provide a sound understanding of the governing processes in the application of alpha-emitters and other radioactive isotopes. Such details will help not only in combating cancer, but also in understanding how low-level radiation exposure effects the human genetic makeup. The hope is to produce a patient-tailored drug and/or therapy design in the future, through studying the specific features of particular diseases and their genetic expression.

Fabio Fabbi | Europäische Kommission
Further information:
http://itu.jrc.cec.eu.int/

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>